Amgen — May 1, 2025 release

This increase reflects an $800 million tax deposit made in the first quarter of 2024 and current quarter business performance, partially offset by timing of working capital items and higher capital expenditures. • The Company declared a first quarter 2025 dividend on December 10, 2024 of $2.38 that was paid on March 7, 2025 to all stockholders of record as of February 14, 2025, representing a 6% increase from the same period in 2024. • During the first quarter of 2025, the Company reduced principal debt outstanding by $2.8 billion. • During the first quarter, there were no repurchases of shares of common stock. • Cash and cash equivalents totaled $8.8 billion and debt outstanding totaled $57.4 billion as of March 31, 2025. $Billions, except shares Q1 ’25 Q1 ’24 YOY Δ Operating Cash Flow $ 1.4  $ 0.7  $ 0.7  Capital Expenditures $ 0.4  $ 0.2  $ 0.2  Free Cash Flow $ 1.0  $ 0.5  $ 0.5  Dividends Paid $ 1.3  $ 1.2  $ 0.1  Share Repurchases $ —  $ —  $ —  Average Diluted Shares (millions) 541  536  5  Note: Numbers may not add due to rounding AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS Page 7 $Billions 3/31/25 12/31/24 YTD Δ Cash and Cash Equivalents $ 8.8  $ 12.0  $ (3.2) Debt Outstanding $ 57.4  $ 60.1  $ (2.7) Note: Numbers may not add due to rounding 2025 Guidance For the full year 2025, the Company expects: • Total revenues in the range of $34.3 billion to $35.7 billion. • On a GAAP basis, EPS in the range of $12.21 to $13.46, and a tax rate in the range of 11.0